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Has gene therapy really taken an unexpected course as transgene expression is needed to achieve a therapeutic effect, and does transgene expression have to be under proposed in the above citation, or is gene therapy just exploring those areas for which the science support is precise regulatory controls; (6) for how long does the transgene need to be expressed to achieve a clinically relmuch stronger? I here wish to contribute to the analysis of why, given that the conceptual basis of gene therapy evant therapeutic effect; and (7) which is the therapeutic objective? has now been accepted by a majority within the scientific community, 2 the largest percentage of clinical trials in To answer these questions requires a comprehensive understanding of the pathophysiological basis of disease, gene therapy are for the treatment or study of cancer (approximately 72%), rather than any other disease; and since knowledge of the aetiology of a disease (ie genetic or environmental), and its pathophysiological mechwhy clinical gene therapy trials for monogenic deficiency disorders, those which initially motivated the developanisms, are the pillars of new successful therapeutic approaches, like gene therapy. Furthermore, knowledge ment of gene therapy, currently only comprise approximately 16% of the total number of clinical trials.
of pathophysiological mechanisms has advanced rapidly in recent years, in parallel with the progress of molecular It has been proposed that most clinical gene therapy trials are for cancer gene therapy, either because of the genetics' push towards the identification of genes mutated or predisposing to human diseases. However, very high proportion of cancer patients that will die from the disease, or because its high incidence constitutes a while genetics does pinpoint individual mutations in the genome as disease-causing mutations, it does not help us large enough patient population for the pharmaceutical industry to direct its vast resources at diseases which can specify in which individual cell that gene's function is essential for normal cellular function. As genetics be developed into large commercial markets. As Roth and Cristiano 1 argue in their recent exhaustive review on uncovers new disease-causing mutations, new tools are being developed to bridge the gap leading from gene cancer gene therapy, according to the historical developments and original interpretation of gene therapy as mutation to pathophysiology. Gene therapy, just as pharmacology, thus needs to have a solid pathophysiological 'replacement gene therapy', it appears somewhat difficult to understand why most gene therapy trials currently tarbasis to its therapeutic implementations in order to become clinically successful. get cancer. In addition, the scientific literature has been ambivalent towards gene therapy's remit, either describLet us now consider the answers to the central questions when considering the implementation of a gene ing it as a therapy limited to 'gene manipulations' for the treatment of inherited diseases, or proposing that it therapy approach to cancer: (1) which vectors? Essentially any and all gene-delivery systems developed so far should encompass any nucleic acid-mediated therapeutics, even if the beneficial effect of the transferred have been adapted for use in cancer gene therapy. 1 Retroviruses can be used to target the dividing tumour cells, nucleic acid is unrelated to any causative genetic mutations, either known or unknown to the investigators. but nonintegrating, high efficiency delivery systems like adenovirus vectors can also be employed, while ex vivo The 1996 edition of Goodman and Gilman's classical pharmacology textbook 3 now includes a chapter on gene approaches facilitate the use of nonviral systems; ongoing clinical trials already are deploying a wide variety of diftherapy. This is the larger scientific field to which gene therapy belongs. In spite of its independent origin and ferent strategies; 1 (2) when to treat? As soon as diagnosis is made. Presymptomatic and preventive treatment heritage, and whether anyone would wish to rename gene therapy, it is part of pharmacology. I believe that might become available in the future for patients with established high genetic risk factors; (3) which organ to conceiving gene therapy as the newest branch of pharma-target? The organ harbouring the tumour itself, and/or so aggressively, because available vector systems can be employed for either cell killing or immune stimulation the bone marrow cells to stimulate an antitumour immune response; (4) which and how many cells to strategies; disease pathophysiology provides clear-cut answers that can be implemented clinically, ie it is obvitransduce? The tumour cells, if possible all, to achieve ous when to treat the disease, which cells to target, and direct cell killing, or lower percentages of tumour cells if thus, most importantly, the therapeutic objective is a strong bystander effect can be demonstrated, or the norunequivocal and is easy to monitor clinically. Many mal surrounding tissue, to stimulate the antitumour answers concerning gene therapy for inherited disorders immune response; (5) what level and regulation of transand their clinical implementation still remain ambiguous, gene expression? Enough to achieve cell killing of human even in the cases in which clinical trials have already tumour cells (this can easily be determined in vitro), or been ongoing (eg the various ADA deficiency trials and release differentiating and activating cytokines to stimu-CF clinical trials, among others). This analysis, however, late the development of the immune response; (6) londoes not imply that the results of the ongoing cancer gene gevity of expression? Short term, to kill the tumour cells, therapy clinical trials will necessarily have a more posior stimulate the immune response; (7) can the therapeutic tive outcome than those for other diseases, but aims to objective be stated clearly? To eliminate or significantly indicate that further advances in our understanding of reduce the growth of the primary tumour and its metdisease pathophysiology will have crucial relevance to astasis.
the further development of successful gene therapy. If we now try to apply these questions to an inherited Thus, explorations of the interplay between disease recessive disorder, like cystic fibrosis (CF), we will realise pathophysiology and gene therapy need to be exploited that answers to some questions are not yet available, and in order to enhance the clinical effectiveness of the future answers to others remain ambiguous: (1) approach to cancer treatment founded on aetiological and of much work in this area and the obvious importance pathophysiological considerations; (3) make full use of of the question, the answer to it remains unclear, with novel technology, are all substantial reasons that make several available possibilities, ie do patients have to be cancer so attractive as a clinical target for gene therapy; treated when symptoms are first diagnosed? or do affecnotwithstanding the severity of the disease, the large ted foetuses have to be treated in utero in order to stop numbers of patients, and the financial interests of the the disease from developing at all? will the treatment of pharmaceutical and biotechnological industry. adults, even by gene therapy, be clinically effective, or has damage already progressed beyond repair in an affected adult? (3) which organ to target? The lungs,
